Collaboration between Alamar Biosciences and DZNE (German Center for Neurodegenerative Diseases) for a pioneering Proteomic Profiling study in the Rhineland Study group cohort
In a significant stride for aging and dementia research, Alamar Biosciences, a privately held life sciences company, has entered into a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE). This partnership aims to leverage Alamar's advanced proteomic tools and the DZNE's extensive population data to accelerate the identification of actionable biomarkers for neurodegenerative diseases.
The collaboration will deploy Alamar's NULISAseqTM CNS Disease Panel 120 and Inflammation Panel 250 in the DZNE's Rhineland Study, a uniquely large and well-characterized cohort. This study, one of the world's most comprehensive and innovative longitudinal aging cohorts, follows thousands of individuals across decades to uncover determinants of healthy aging and neurodegeneration.
Using Alamar's comprehensive proteomic tools enables high-resolution profiling of protein biomarkers associated with neurodegenerative processes and age-related biological changes. The CNS panel, for instance, has the ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in plasma. On the other hand, the Inflammation Panel 250 provides the most comprehensive and sensitive profiling of immune-related proteins.
This partnership is important in the context of biomarker discovery because it applies advanced proteomic technology to a large cohort, increasing the statistical power and potential to identify novel biomarkers. The focus on both central nervous system-related and inflammatory proteins reflects the complex interplay between neuroinflammation and neurodegeneration, central to conditions like Alzheimer's disease and other disorders. Access to such a large dataset allows better understanding not only of pathological processes but also of markers linked to healthy aging, improving differentiation between disease and normal aging states.
The goal of this collaboration is to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies. Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences, stated that this partnership is a major step forward in aging and dementia research.
Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized in the DZNE Rhineland Study to enable deep insights into the aging brain. The resulting proteomic data will be combined with these extensive clinical, demographic, and imaging datasets.
For more information, visit www.rheinland-studie.de/en/ for the DZNE Rhineland Study and www.dzne.de/en/ for the DZNE. To learn more about Alamar Biosciences, visit alamarbio.com.
The collaboration between DZNE and Alamar Biosciences is poised to drive earlier diagnosis, improved prognosis, and new therapeutic pathways for age-related brain disorders, ultimately transforming diagnosis, monitoring, and treatment of neurodegenerative diseases while providing insights into the biology of healthy aging.
This partnership between Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) is focused on identifying actionable biomarkers for neurodegenerative diseases, such as Alzheimer's disease, through the use of Alamar's advanced proteomic tools. The collaboration aims to better understand pathological processes, markers linked to healthy aging, and the complex interplay between neuroinflammation and neurodegeneration in medical-conditions like Alzheimers-disease and other neurological-disorders.
%20for%20a%20pioneering%20Proteomic%20Profiling%20study%20in%20the%20Rhineland%20Study%20group%20cohort){kind=link}